A Rose Brannon
Overview
Explore the profile of A Rose Brannon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
3458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arora K, Suehnholz S, Zhang H, Ostrovnaya I, Kundra R, Nandakumar S, et al.
JAMA Oncol
. 2025 Jan;
PMID: 39786754
Importance: Although differences in the prevalence of key cancer-specific somatic mutations as a function of genetic ancestry among patients with cancer has been well-established, few studies have addressed the practical...
2.
Varghese A, Perry M, Chou J, Nandakumar S, Muldoon D, Erakky A, et al.
Nat Med
. 2025 Jan;
31(2):466-477.
PMID: 39753968
Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by KRAS exon 2 mutations. Most patients with PDAC present with advanced disease and are treated with cytotoxic therapy. Genomic biomarkers prognostic...
3.
Kim D, Vanderbilt C, Yang S, Nandakumar S, Nafa K, Feratovic R, et al.
Nat Commun
. 2025 Jan;
16(1):116.
PMID: 39747849
Comprehensive molecular profiling by next-generation sequencing has revolutionized tumor classification and biomarker evaluation. However, routine implementation is challenged by the scant nature of diagnostic material obtained through minimally invasive procedures....
4.
Ziegler J, Hechtman J, Rana S, Ptashkin R, Jayakumaran G, Middha S, et al.
Nat Commun
. 2025 Jan;
16(1):136.
PMID: 39746944
Microsatellite instability (MSI) is a critical phenotype of cancer genomes and an FDA-recognized biomarker that can guide treatment with immune checkpoint inhibitors. Previous work has demonstrated that next-generation sequencing data...
5.
Zucker M, Perry M, Gould S, Elkrief A, Safonov A, Thummalapalli R, et al.
Cell
. 2024 Dec;
188(3):851-867.e17.
PMID: 39701102
The canonical model of tumor suppressor gene (TSG)-mediated oncogenesis posits that loss of both alleles is necessary for inactivation. Here, through allele-specific analysis of sequencing data from 48,179 cancer patients,...
6.
Jee J, Fong C, Pichotta K, Tran T, Luthra A, Waters M, et al.
Nature
. 2024 Nov;
636(8043):728-736.
PMID: 39506116
The digitization of health records and growing availability of tumour DNA sequencing provide an opportunity to study the determinants of cancer outcomes with unprecedented richness. Patient data are often stored...
7.
Hickman R, Miller A, Holle B, Jee J, Liu S, Ross D, et al.
Acta Neuropathol Commun
. 2024 Sep;
12(1):151.
PMID: 39289779
The characterization of genetic alterations in tumor samples has become standard practice for many human cancers to achieve more precise disease classification and guide the selection of targeted therapies. Cerebrospinal...
8.
Jee J, Brannon A, Singh R, Derkach A, Fong C, Lee A, et al.
Nat Med
. 2024 Aug;
30(9):2499-2507.
PMID: 39147831
Cancer-associated venous thromboembolism (VTE) is a major source of oncologic cost, morbidity and mortality. Identifying high-risk patients for prophylactic anticoagulation is challenging and adds to clinician burden. Circulating tumor DNA...
9.
Krystel-Whittemore M, Petrova-Drus K, Ptashkin R, Ewalt M, Yao J, Liu Y, et al.
Haematologica
. 2024 Mar;
109(10):3269-3281.
PMID: 38450530
Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients' management. In this context, unequivocally discriminating somatic from germline events is...
10.
Stonestrom A, Menghrajani K, Devlin S, Franch-Exposito S, Ptashkin R, Patel S, et al.
Blood Adv
. 2023 Dec;
8(4):846-856.
PMID: 38147626
Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) ≥ 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader...